Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
Genpact Ltd (G) reported that its Chief Financial Officer filed a Form 4 disclosing an open-market sale of company stock. On 11/14/2025, the CFO sold 13,365 common shares of Genpact at a weighted average price of $44.84 per share, with individual sale prices ranging from $44.81 to $44.89. Following this transaction, the reporting person beneficially owns 148,026 Genpact common shares. This total includes 1,358 shares held under the Genpact Employee Stock Purchase Plan, of which 169 shares were acquired under the plan since a prior report filed on March 13, 2025.
Genpact UK Finco plc and Genpact USA, Inc. priced a $350,000,000 offering of 4.950% Senior Notes due 2030, fully and unconditionally guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes mature on November 18, 2030 and pay interest semi-annually on May 18 and November 18, starting May 18, 2026.
The notes were offered at 99.593% with a 0.400% underwriting discount, resulting in proceeds before expenses of $347,175,500; Genpact estimates net proceeds of approximately $345.4 million. The company intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming the 1.750% Senior Notes due 2026, of which approximately $350 million is outstanding, at or prior to their April 10, 2026 maturity.
The notes are senior unsecured obligations with optional redemption at a make‑whole premium before October 18, 2030 and at par thereafter, and include a change of control repurchase at 101% of principal. Genpact plans to apply to list the notes on The International Stock Exchange; there is currently no public market.
Form 144 filing: A holder notified intent to sell up to 13,365 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/14/2025. The filing lists an aggregate market value of $599,314.67 for the planned sale.
The shares were acquired as restricted stock from the issuer on 08/02/2022. As context, 172,414,423 shares were outstanding at the time referenced.
Genpact (G) reported insider transactions by its SVP & Chief Legal Officer. On 11/11/2025, the officer sold 1,039 common shares at $44.02. On 11/12/2025 and 11/13/2025, the officer exercised employee stock options at $27.7 for 4,351 and 45,703 shares, respectively, and sold the corresponding shares at $45.74. Following these transactions, the officer directly beneficially owned 50,569 common shares. The reported option grant was scheduled to expire on 01/09/2029 and vested 50% on January 10, 2022 and 50% on January 10, 2024.
Genpact Ltd (G) — Form 4 insider transaction: Senior Vice President Sameer Dewan reported a sale of 26,531 common shares on 11/11/2025, coded “S” for sale. The weighted average price was $44.7, with disclosed trade prices ranging from $44.70 to $44.7305.
Following the transaction, Dewan beneficially owns 62,617 shares, held directly.
Genpact Ltd (G) director Tamara Franklin reported a sale of 2,750 common shares at $45.65 on November 12, 2025, according to a Form 4 filing. Following the transaction, she beneficially owns 22,236 shares, held directly. The filing lists a transaction code “S,” indicating a sale, and shows no derivative securities activity reported.
G: A selling holder filed a Form 144 notice to sell 45,703 shares of common stock with an aggregate market value of $2,090,455.22, through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/13/2025 on the NYSE.
The shares were acquired via a stock option exercise on 11/13/2025 for cash. In the past three months, HEATHER D WHITE reported sales of 4,351 shares for $199,014.74 on 11/12/2025 and 1,039 shares for $45,731.59 on 11/11/2025. Shares outstanding were 172,414,423.
Genpact UK Finco plc and Genpact USA, Inc. plan a primary offering of senior unsecured notes due 2030, fully and unconditionally guaranteed by Genpact Limited and Genpact Luxembourg S.à r.l. The notes pay interest semi-annually beginning in 2026 and rank pari passu with the issuers’ other senior unsecured debt.
The issuers may redeem the notes at any time before one month prior to maturity at a make‑whole price, and at par thereafter; a change of control repurchase event requires a 101% offer to holders. The issuers intend to apply to list the notes on The International Stock Exchange.
Use of proceeds: general corporate purposes, which may include repaying or redeeming the 1.750% senior notes due 2026; approximately $350 million of those 2026 notes are outstanding. As of September 30, 2025, Genpact had $1.2 billion of unsecured indebtedness outstanding and undrawn revolving credit availability of $648.74 million.
Genpact Limited filed an automatic shelf registration (Form S-3) that allows it—and certain subsidiaries as co-issuers—to offer, from time to time after effectiveness, debt securities (with potential guarantees), common shares, preference shares, depositary shares, warrants, and units. Any specific terms and amounts will be set in future prospectus supplements. The company states it may sell directly, through agents, or via underwriters and dealers.
Net proceeds from any future primary offerings will be used for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, and capital expenditures. Genpact’s common shares trade on the NYSE under “G.” Shares outstanding were 172,414,423 as of November 3, 2025; this is a baseline figure, not the amount being offered.
G reported a Form 144 notice indicating a planned sale of up to 2,750 shares of common stock. The filing lists an aggregate market value of $125,537.50 and identifies Morgan Stanley Smith Barney LLC as the broker. The shares are expected to be sold on the NYSE with an approximate sale date of 11/12/2025.
The seller acquired 2,750 shares as restricted stock from the issuer on 12/31/2021 with “Not Applicable” listed for payment terms. Shares outstanding were 172,414,423; this is a baseline figure, not the amount being offered.